OSL •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOSL
Market Capitalization1,644.49 mln
Float214 mln
Earnings Date11/25/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
6.25
Exceptional upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-24.75
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Nykode Therapeutics is a Norwegian medical company based in Oslo that creates new treatments for cancer, autoimmune conditions, and infectious diseases. Its two most advanced experimental medicines are VB10.NEO, a personalized cancer vaccine currently in early-stage human trials, and VB10.16, a vaccine targeting cancers caused by the human papillomavirus, which is now in mid-stage trials. Founded in 2006, the company focuses on harnessing the body's immune system to fight disease.
